Chapters

Transcript

Video

Since the efficacy of biosimilars is typically studied for a single indication, why are approvals of such biosimilars as INFLIXIMAB-DYYB extended to other diseases in which the biosimilar was not tested directly against the reference


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA